Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients.
Ghady HaidarJana L JacobsKailey Hughes KramerAsma NaqviAmy HeapsUrvi ParikhKevin D McCormickMichele D SobolewskiMounzer AghaTatiana BogdanovichVasilii BushunowRafic FarahMatthew HensleyYen-Michael S HsuBruce JohnsonCynthia Klamar-BlainJennifer KozarElizabeth LendermonBernard Jc MacatangayChristopher C MarinoAnastasios RaptisErin SaleseFernanda P SilveiraAnn M LeenWilliam L MarshallMichael MillerBadrish PatelErcem AtillasoyJohn W MellorsPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
We administered SARS-CoV-2 VST under emergency IND to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses: three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VST in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to two courses of remdesivir and experienced sustained recovery after VST. The use VST in immunocompromised patient with persistent COVID-19 requires further study.
Keyphrases
- sars cov
- end stage renal disease
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- healthcare
- stem cells
- bone marrow
- respiratory syndrome coronavirus
- case report
- mesenchymal stem cells
- patient reported
- patient reported outcomes
- mechanical ventilation
- acute respiratory distress syndrome